Barinthus Biotherapeutics plc (FRA:2AB)

Germany flag Germany · Delayed Price · Currency is EUR
0.4600
-0.0020 (-0.43%)
At close: Mar 27, 2026
Market Cap19.50M -50.3%
Revenue (ttm)n/a
Net Income-56.58M
EPS-1.40
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open0.4600
Previous Close0.4620
Day's Range0.4600 - 0.4600
52-Week Range0.4500 - 1.5400
Betan/a
RSI39.99
Earnings DateMay 7, 2026

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Employees 14
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 2AB
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements